Key result
Genomic testing identifies likely pathogenic MYBPC3 variants in three Ecuadorian men with HCM.
Why the study?
Although MYBPC3 is the most frequently implicated gene in hypertrophic cardiomyopathy, data from Latin American and admixed populations remain scarce.
Case Report (n=3)
No
This case series highlights the phenotypic heterogeneity of MYBPC3-related HCM and the importance of genomic testing in underrepresented admixed populations for diagnosis and sudden cardiac death risk stratification.
May support genomic testing for HCM in admixed populations; leaves open validation for SCD risk stratification.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and a leading cause of sudden cardiac death (SCD) in young adults and athletes. It exhibits marked clinical variability, which may be influenced by genetic background and environmental factors. Although MYBPC3 is the most frequently implicated gene, data from Latin American and admixed populations remain scarce. In this study, we describe three unrelated Ecuadorian patients with clinically diagnosed HCM who harbored MYBPC3 variants. Two patients carried likely pathogenic mutations (p.Glu258Lys and p.His875Profs*8), while novel missense variants (p.Ala536Pro and p.Thr274Met) were identified as variants of uncertain significance (VUS). Additional variants were detected in TTN , MYLK2 , RYR1 , SDHA , APOB , and JPH2 , but given their classification as VUS or a lack of association with HCM, they are described only as incidental findings. An ancestry analysis revealed heterogeneous contributions of Native American, European, and African backgrounds, reflecting the admixed composition of the Ecuadorian population. This case series underscores the phenotypic heterogeneity of HCM, even among patients with MYBPC3 variants, and highlights the importance of genomic testing in underrepresented populations to improve diagnosis, family screening, and SCD risk stratification.
No takes yet. Share an insight, caveat, or question.
Paz-Cruz et al. (2026) conducted a case report in Hypertrophic cardiomyopathy (n=3). Genomic testing (Next-generation sequencing) was evaluated on Identification of genetic variants associated with hypertrophic cardiomyopathy. Genomic testing in three unrelated Ecuadorian men with hypertrophic cardiomyopathy identified two likely pathogenic MYBPC3 variants and two novel variants of uncertain significance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: